UP!
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2022 | 2022-11-02 | Future report Set alerts | |
| Q2 2022 | 2022-08-04 | 0.23 | 0.23 |
| Q1 2022 | 2022-05-09 | -0.35 | -0.35 |
| Q4 2021 | 2022-03-01 | -0.40 | -0.40 |
| Q3 2021 | 2021-11-04 | -0.34 | -0.34 |
| Q2 2021 | 2021-08-05 | -0.51 | -0.51 |
| Q1 2021 | 2021-05-10 | -0.45 | -0.45 |
| Q4 2020 | 2021-02-25 | -0.60 | -0.60 |
| Q3 2020 | 2020-11-05 | -0.42 | -0.42 |
| Q2 2020 | 2020-08-10 | -1.28 | -1.28 |
| 2016-07-12 | Reiterated Rating | Credit Suisse Group AG | Hold | |
| 2016-05-16 | Reiterated Rating | HC Wainwright | Buy | |
| 2016-05-08 | Reiterated Rating | Brean Capital | Buy | |
| 2016-05-08 | Reiterated Rating | Morgan Stanley | Buy | |
| 2016-03-16 | Initiated Coverage | Brean Capital | Buy | |
| 2016-03-16 | Lower Price Target | Needham & Company LLC | Buy | $18.00 to $14.00 |
| 2016-03-16 | Lower Price Target | HC Wainwright | Buy | $25.00 to $18.00 |
| 2016-03-10 | Lower Price Target | HC Wainwright | Buy | $25.00 to $18.00 |
| 2016-03-10 | Initiated Coverage | Brean Capital | Buy | $26.00 |
| 2016-03-09 | Lower Price Target | JMP Securities | Market Outperform | $24.00 to $16.00 |
| 2016-03-09 | Lower Price Target | JPMorgan Chase & Co. | Market Outperform | $24.00 to $16.00 |
| 2016-01-20 | Initiated Coverage | Credit Suisse | Neutral | $10.00 |
| 2016-01-20 | Initiated Coverage | Credit Suisse Group AG | Neutral | $10.00 |
| 2015-12-15 | Reiterated Rating | Brean Capital | Buy | |
| 2015-12-15 | Boost Price Target | HC Wainwright | Buy | $24.00 to $25.00 |
| 2015-12-14 | Boost Price Target | Needham & Company LLC | Buy | $14.00 to $18.00 |
| 2015-12-07 | Initiated Coverage | HC Wainwright | Buy | $24.00 |
| 2015-11-10 | Reiterated Rating | Brean Capital | Buy | $26.00 |
| 2015-10-06 | Initiated Coverage | Brean Capital | Buy | |
| 2015-10-06 | Reiterated Rating | Needham & Company LLC | Buy | $14.00 |
| 2015-09-29 | Reiterated Rating | Brean Capital | Buy | $26.00 |
| 2015-09-09 | Upgrade | Morgan Stanley | Equal Weight to Overweight | $10.00 to $17.00 |
| 2015-09-09 | Boost Price Target | Brean Capital | Buy | $18.00 to $26.00 |
| 2015-08-13 | Initiated Coverage | Morgan Stanley | Equal to Equal Weight | $10.00 |
| 2015-08-12 | Reiterated Rating | Brean Capital | Buy | $18.00 |
| 2015-06-22 | Initiated Coverage | JMP Securities | Outperform | $24.00 |
| 2015-06-04 | Set Price Target | Brean Capital | Buy | $18.00 |
| 2015-05-14 | Initiated Coverage | Brean Capital | Buy | $18.00 |
| 2015-05-12 | Reiterated Rating | Nomura | Buy | $37.00 to $27.00 |
| 2015-05-12 | Reiterated Rating | Nomura Holdings Inc. | Buy | $37.00 to $27.00 |
| 2015-05-11 | Initiated Coverage | Needham & Company LLC | Buy | $14.00 |
| 2014-11-07 | Reiterated Rating | Nomura | Buy | $39.00 |
| 2014-04-14 | Initiated | |||
| 2014-04-14 | Initiated Coverage | Nomura | Buy | $39.00 to $16.86 |
| 2014-04-14 | Initiated Coverage | Credit Suisse | Outperform | $25.00 |
| 2014-04-14 | Initiated Coverage | Morgan Stanley | Overweight | $90.00 |
| 2016-07-12 | Reiterated Rating | Credit Suisse Group AG | Hold | |
| 2016-05-16 | Reiterated Rating | HC Wainwright | Buy | |
| 2016-05-08 | Reiterated Rating | Brean Capital | Buy | |
| 2016-05-08 | Reiterated Rating | Morgan Stanley | Buy | |
| 2016-03-16 | Initiated Coverage | Brean Capital | Buy |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In AKBA 0 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| Novartis Bioventures Ltd | 16.81% (3405764) | AKBA / CLDN / MRNA / PIP / TKAI / |
| Satter Muneer A | 14.99% (3037042) | AKBA / TKAI / VTL / |
| Novo A/S SEE REMARKS | 7.48% (1516387) | AKBA / ALDR / CRVS / FLXN / INGN / LPTN / OPHT / OTIC / RETA / RGDO / ZSPH / |
| Butler John P. President and CEO | 2.02% (408814) | AKBA / KERX / RLYP / |
| Shalwitz Robert Chief Medical Officer | 1.31% (264556) | AKBA / |
| Hadas Nicole R. See Remarks | 0.59% (120078) | AKBA / |
| Dahan Michel SVP, Chief Business Officer | 0.57% (115226) | AKBA / |
| Amello Jason SVP, CFO & Treasurer | 0.43% (87236) | AKBA / OPXA / ZIOP / |
| Maroni Bradley SVP & Chief Medical Officer | 0.32% (64585) | AKBA / |
| Tubridy Karen L SVP, Chief Development Officer | 0.20% (41518) | AKBA / EBIO / |
| Jain Rita SVP, Chief Medical Officer | 0.15% (29400) | AKBA / |
| Nash Duane | 0.11% (21499) | AKBA / VTL / |
| Renaud Ronald C JR | 0.02% (5000) | AKBA / CMRX / IDIX / PTCT / |
| WYZGA MICHAEL S | 0.01% (1500) | AKBA / EXAS / IDIX / OMED / RDUS / |
| GOWEN MAXINE | 0.01% (1300) | AKBA / IDRA / TRVN / |
UM